Sagent Pharmaceuticals acquires Omega Laboratories

Sagent Pharmaceuticals, Inc., a leader of specialty pharmaceutical products with an emphasis on the injectable market, completed its acquisition of Omega Laboratories Limited, a market leading specialty pharmaceutical company based in Montreal, for approximately US$85.3 million (C$95 million) in cash. The combination of Sagent and Omega creates a premier generic injectable company with a robust product portfolio, deep development pipeline and strong global presence.


Sagent was represented in the US by Alexander Fine and George Stamas of
Kirkland & Ellis LLP; and in Canada by Brian Pukier, Kim Le and Julien Lefebvre (M&A); John Lorito, Katy Pitch and Dominic Bédard-Lapointe (tax); Stephanie Weschler and Frédéric Henry (employment); Richard Rusk (environmental); Neil Bindman (real estate) and Ashley Piotrowski (competition) of Stikeman Elliott LLP.

Omega was represented by Fasken Martineau DuMoulin LLP with a team led by Patrice Vachon, and including Marie-Eve Clavet, Kiran Singh, Anabel Quessy, Joëlle Simard, Pierre-Olivier Charlebois, Emilie Bundock and Alain Ranger.